Brought to you by 
Juno buys Stage Cell Therapeutics for €52mm plus €135mm in earn-outs
May 2015
Executive Summary
Juno Therapeutics Inc. paid €52mm ($59mm) in cash and issued 486k of its shares (valued at €20mm) to acquire the 95% of German biotech Stage Cell Therapeutics GMBH that it didn’t already down. Stage Cell will operate as a wholly owned subsidiary, and will be renamed Juno Therapeutics GMBH.
Deal Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Payment Includes Cash
- Partial Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Stock
- Includes Contract
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Juno buys Stage Cell Therapeutics for €52mm plus €135mm in earn-outs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice